Humana Inc. (NYSE:HUM) Shares Bought by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC raised its holdings in shares of Humana Inc. (NYSE:HUM) by 6.1% in the 4th quarter, HoldingsChannel reports. The fund owned 1,509 shares of the insurance provider’s stock after buying an additional 87 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Humana were worth $388,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HUM. FPC Investment Advisory Inc. acquired a new position in Humana in the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC acquired a new stake in Humana during the fourth quarter worth approximately $30,000. LFA Lugano Financial Advisors SA lifted its position in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Humana in the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. grew its position in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

HUM has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Barclays boosted their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Royal Bank of Canada restated an “outperform” rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Truist Financial lifted their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Eighteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Trading Up 0.2 %

Shares of HUM stock opened at $265.20 on Thursday. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The business’s fifty day moving average price is $268.97 and its 200 day moving average price is $272.62. The firm has a market capitalization of $32.01 billion, a PE ratio of 26.65, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.